This week, pharmaceutical giant Eli Lilly (LLY) announced a new acquisition agreement, under which it will purchase Merida Biosciences for $2.9 billion, further enriching its already substantial drug development pipeline. The core of this acquisition lies in Merida’s focus on developing drugs that can selectively degrade pathogenic autoantibodies, which are the root cause of multiple immune-mediated diseases. Unlike many traditional autoimmune therapies that broadly suppress the entire immune system, Merida’s investigational therapies are designed to precisely target specific pathogens while avoiding interference with normal immune processes, representing a new direction in the autoimmune treatment field.
Merida’s most advanced candidate drug, MER511, has entered Phase 1 clinical development for Graves’ disease and thyroid eye disease. Graves’ disease is an autoimmune disorder affecting approximately 3 million patients in the United States, a considerable proportion of whom go on to develop thyroid eye disease, leading to ocular discomfort, protrusion, and even visual impairment, representing a significant unmet clinical need. By bringing MER511 into its portfolio, Lilly is poised to offer more targeted treatment options for such patients in the future.
Lilly is already a leader in the rapidly growing global GLP-1 drug market, with robust demand for its diabetes and obesity treatments. According to data from healthcare research institute IQVIA, the global obesity drug market reached $66 billion in 2025, is expected to climb to $92 billion this year, and could reach between $105 billion and $200 billion by 2027, with continued growth thereafter. It is the immense commercial success of GLP-1 drugs that has provided ample financial backing for Lilly’s frequent large-scale acquisitions in recent years.
26 Deals in Two Years, Building a Diversified Pharmaceutical Empire
In fact, the acquisition of Merida is merely the latest step in Lilly’s vast expansion plan. Since 2023, the company has completed approximately 26 acquisitions, many of which have exceeded $1 billion, with targets spanning a wide range of therapeutic areas including oncology, sleep disorders, immunology, infectious diseases, ophthalmology, pain, cardiovascular disease, inflammation, neurological disorders, obesity, and diabetes. This high-frequency, broad-coverage M&A strategy continues to reinforce the foundation for its future performance growth.
The confidence behind Lilly’s acquisitions comes directly from the blockbuster sales performance of its core product, tirzepatide. Sold under the brands Mounjaro (for type 2 diabetes) and Zepbound (for obesity), the drug surpassed Merck’s Keytruda last year to become the world’s best-selling medicine. In the second quarter of this year alone, Mounjaro generated $9.9 billion in sales, up 91% year-over-year, while Zepbound’s revenue grew 44% to $4.9 billion. These two figures amply demonstrate the strength of its cash flow.
In summary, Lilly is fully leveraging the immense cash flow generated by its GLP-1 drugs to proactively position itself in cutting-edge therapeutic areas such as autoimmunity through systematic, high-frequency acquisitions, thereby building a diversified and more resilient product portfolio. Against the backdrop of accelerating global population aging, upgrading medical demand in emerging markets, and the healthcare sector’s inherent defensive characteristics, Lilly maintains a notably competitive stance within the pharmaceutical industry, underpinned by its established market leadership and highly aggressive pipeline expansion strategy.
